BACKGROUND: The circumferential resection margin (CRM) is a strong prognostic factor in rectal cancer. The purpose of this study was to investigate the relationship between CRM distance and recurrence in patients with locally advanced rectal cancer who received preoperative chemoradiotherapy (CRT). METHODS: We analyzed data for 561 patients who underwent preoperative CRT and curative surgery for locally advanced rectal cancer between August 2001 and December 2008. CRM was divided into four groups: group 1, CRM > 2 mm; group 2, 1.1-2.0 mm; group 3, 0.1-1.0 mm; and group 4, 0 mm. We assessed the associations of CRM with local recurrence and disease-free survival. RESULTS: Groups 1, 2, 3, and 4 comprised 487, 36, 20, and 18 patients, respectively. The local recurrence rate was highest and the disease-free survival rate was lowest in group 4, followed by groups 3, 2, and 1. Survival was similar between groups 2 and 1. Local recurrence rates were lower in groups 3, 2, and 1 than in group 4 [hazard ratio (HR) 0.28, 95 % confidence interval (CI) 0.09-0.91, P = 0.035; HR 0.11, 95 % CI 0.03-0.46, P = 0.002; HR 0.18, 95 % CI 0.08-0.42, P < 0.0001, respectively]. Disease-free survival rates were higher in groups 3, 2, and 1 than in group 4 (HR 0.32, 95 % CI 0.13-0.75, P = 0.009; HR 0.24, 95 % CI 0.10-0.54, P = 0.001; HR 0.26, 95 % CI 0.14-0.48, P < 0.0001, respectively). CONCLUSIONS: After preoperative CRT, CRM distance provides useful information for risk stratification in the recurrence of rectal cancer.
BACKGROUND: The circumferential resection margin (CRM) is a strong prognostic factor in rectal cancer. The purpose of this study was to investigate the relationship between CRM distance and recurrence in patients with locally advanced rectal cancer who received preoperative chemoradiotherapy (CRT). METHODS: We analyzed data for 561 patients who underwent preoperative CRT and curative surgery for locally advanced rectal cancer between August 2001 and December 2008. CRM was divided into four groups: group 1, CRM > 2 mm; group 2, 1.1-2.0 mm; group 3, 0.1-1.0 mm; and group 4, 0 mm. We assessed the associations of CRM with local recurrence and disease-free survival. RESULTS: Groups 1, 2, 3, and 4 comprised 487, 36, 20, and 18 patients, respectively. The local recurrence rate was highest and the disease-free survival rate was lowest in group 4, followed by groups 3, 2, and 1. Survival was similar between groups 2 and 1. Local recurrence rates were lower in groups 3, 2, and 1 than in group 4 [hazard ratio (HR) 0.28, 95 % confidence interval (CI) 0.09-0.91, P = 0.035; HR 0.11, 95 % CI 0.03-0.46, P = 0.002; HR 0.18, 95 % CI 0.08-0.42, P < 0.0001, respectively]. Disease-free survival rates were higher in groups 3, 2, and 1 than in group 4 (HR 0.32, 95 % CI 0.13-0.75, P = 0.009; HR 0.24, 95 % CI 0.10-0.54, P = 0.001; HR 0.26, 95 % CI 0.14-0.48, P < 0.0001, respectively). CONCLUSIONS: After preoperative CRT, CRM distance provides useful information for risk stratification in the recurrence of rectal cancer.
Authors: Francesco Feroci; Andrea Vannucchi; Paolo Pietro Bianchi; Stefano Cantafio; Alessia Garzi; Giampaolo Formisano; Marco Scatizzi Journal: World J Gastroenterol Date: 2016-04-07 Impact factor: 5.742
Authors: Molly A Wasserman; Michael F McGee; Irene B Helenowski; Amy L Halverson; Anne-Marie Boller; Steven J Stryker Journal: Int J Colorectal Dis Date: 2015-11-25 Impact factor: 2.571
Authors: Martin C Boonstra; Pieter B A A van Driel; Danny M van Willigen; Marieke A Stammes; Hendrica A J M Prevoo; Quirijn R J G Tummers; Andrew P Mazar; Freek J Beekman; Peter J K Kuppen; Cornelis J H van de Velde; Clemens W G M Löwik; John V Frangioni; Fijs W B van Leeuwen; Cornelis F M Sier; Alexander L Vahrmeijer Journal: Oncotarget Date: 2015-06-10
Authors: Seung Ho Song; Jun Seok Park; Gyu-Seog Choi; An Na Seo; Soo Yeun Park; Hye Jin Kim; Sung-Min Lee; Ghilsuk Yoon Journal: Sci Rep Date: 2021-11-25 Impact factor: 4.379
Authors: Radwan Torky; Mohammed Alessa; Ho Seung Kim; Ahmed Sakr; Eman Zakarneh; Fozan Sauri; Heejin Bae; Nam Kyu Kim Journal: Ann Coloproctol Date: 2020-09-18